<p><strong>Mantle Cell Lymphoma</strong>: Ibrutinib is indicated for the treatment of patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy.<br />
<br />
<strong>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</strong>: Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukemia.<br />
<br />
<strong>Waldenstrom Macroglobulinemia (WM)</strong>: Ibrutinib is indicated for the treatment of patients with Waldenstrom Macroglobulinemia (WM).<br />
<br />
<strong>Marginal Zone Lymphoma</strong>: Ibrutinib is indicated for the&nbsp; reatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD 20-based therapy.</p>